These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9024933)

  • 41. Whole-body hyperthermia as an adjuvant to treatment with platinum complexes with or without etanidazole in mice bearing the Lewis lung carcinoma or the FSaLL fibrosarcoma.
    Teicher BA; Herman TS; Menon K; Korbut TT
    Int J Hyperthermia; 1992; 8(6):783-94. PubMed ID: 1479204
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fractionated thermochemotherapy in vivo of a C3H mouse mammary carcinoma.
    Monge OR; Rofstad EK
    Radiother Oncol; 1991 Jul; 21(3):171-8. PubMed ID: 1924852
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Studies on fractionated hyperthermia in experimental animal systems II. Response of murine tumors to two or more doses.
    Urano M; Rice LC; Montoya V
    Int J Radiat Oncol Biol Phys; 1982 Feb; 8(2):227-33. PubMed ID: 7085378
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of hyperthermia on the early and late appearing mouse foot reactions and on the radiation carcinogenesis: effect on the early and late appearing reactions.
    Urano M; Kenton LA; Kahn J
    Int J Radiat Oncol Biol Phys; 1988 Jul; 15(1):159-66. PubMed ID: 3391813
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thermal enhancement of melphalan and oxaliplatin cytotoxicity in vitro.
    Urano M; Ling CC
    Int J Hyperthermia; 2002; 18(4):307-15. PubMed ID: 12079586
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preclinical phase II study of ifosfamide in human tumour xenografts in vivo.
    Berger DP; Fiebig HH; Winterhalter BR; Wallbrecher E; Henss H
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S7-11. PubMed ID: 2347054
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cepharanthine enhances in vitro and in vivo thermosensitivity of a mouse fibrosarcoma, FSa-II, based on increased apoptosis.
    Wang Y; Kuroda M; Gao XS; Akaki S; Asaumi J; Okumura Y; Shibuya K; Kawasaki S; Joja I; Kato H; Himei K; Dendo S; Kanazawa S; Hiraki Y
    Int J Mol Med; 2004 Mar; 13(3):405-11. PubMed ID: 14767571
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The accelerated repopulation of a murine fibrosarcoma, FSA-II, during the fractionated irradiation and the linear-quadratic model.
    Abe Y; Urano M; Kenton LA; Kahn J; Willet CG
    Int J Radiat Oncol Biol Phys; 1991 Nov; 21(6):1529-34. PubMed ID: 1938563
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of tumor size on S-2-(3-aminopropylamino)ethylphosphorothioic acid and misonidazole alteration of tumor response to cyclophosphamide.
    Milas L; Ito H; Hunter N
    Cancer Res; 1983 Jul; 43(7):3050-6. PubMed ID: 6303574
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo.
    Kusumoto T; Holden SA; Ara G; Teicher BA
    Int J Hyperthermia; 1995; 11(4):575-86. PubMed ID: 7594810
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interaction of D,L- and D-tetraplatin with hyperthermia in vitro and in vivo.
    Epelbaum R; Teicher BA; Holden SA; Ara G; Varshney A; Herman TS
    Eur J Cancer; 1992; 28A(4-5):794-800. PubMed ID: 1524897
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Subrenal capsule assay applied to examine the sensitivity of allogenic mouse fibrosarcoma to hyperthermia, chemotherapeutic drugs or combined treatment.
    Sato S; Ootsuyama A; Hamada M; Tanooka H
    Int J Hyperthermia; 1987; 3(2):177-82. PubMed ID: 3110329
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
    Murata R; Horsman MR
    Int J Hyperthermia; 2004 Jun; 20(4):393-404. PubMed ID: 15204520
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined effects of an angiogenesis inhibitor (TNP-470) and hyperthermia.
    Nishimura Y; Murata R; Hiraoka M
    Br J Cancer; 1996 Feb; 73(3):270-4. PubMed ID: 8562329
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization.
    Hokland SL; Horsman MR
    Int J Hyperthermia; 2007 Nov; 23(7):599-606. PubMed ID: 18038290
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice.
    Badary OA
    J Ethnopharmacol; 1999 Nov; 67(2):135-42. PubMed ID: 10619376
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans.
    Lokiec F; Santoni J; Weill S; Tubiana-Hulin M
    Anticancer Drugs; 1996 Nov; 7(8):893-6. PubMed ID: 8991196
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increased tumour response of a murine fibrosarcoma to low temperature hyperthermia and low dose rate brachytherapy.
    Ryu S; Brown SL; Kolozsvary A; Kim JH
    Int J Hyperthermia; 1996; 12(5):635-43. PubMed ID: 8886890
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Modification of alkylating agent induced cell kill by 2-nitroimidazoles in unclamped and clamped SC 9L tumors.
    Wallen CA; Moore SK; Wheeler KT
    Int J Radiat Oncol Biol Phys; 1992; 22(4):727-30. PubMed ID: 1531976
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Ifosfamide and the metabolites of side chain oxidation--excretion in urine in various pediatric therapeutic protocols].
    Boos J; Welslau U; Ritter J; Blaschke G; Schellong G
    Klin Padiatr; 1992; 204(4):299-305. PubMed ID: 1518269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.